Cariprazine in therapy of visual hallucinations. Randomized, double-blind placebo-controlled study

Objective: We studied cariprazine in therapy of visual hallucinations with a therapeutic resistance due to traumatic brain injury randomized, double-blind placebo-controlled study manner. Methods: To traumatic brain injury hundred patients (100 all men) whom we studied were under observation in Mental Health Center of the Ministry of Health of the Republic of Azerbaijan from January 2020 to June 2021. The method of randomization was given by lottery []. Each patient was randomized to receive either in agreement of the instruction cariprazine (50 patients) over 5 day in dose 6 mg one times per os in morning after meet for 12 weeks or matched placebo (50 patients) in a double-blind manner. A structured clinical interview, for DSM-5Axis I Disorder, Patient Edition, was used to diagnose according to DSM-5 major or mild neurocognitive disorder due to traumatic brain injury. Results: All patients (50) treated with cariprazine treated participants responded by 12 weeks, versus two of the 50 placebo-treated participants (p<0.001). The most common and problematic side effect in the cariprazine group was not. Conclusions: The authors believe this to be the first double-blind placebo-controlled randomization study to test the efficacy of a cariprazine in the management of in therapy of visual hallucinations with a therapeutic resistance due to traumatic brain injury randomized, double-blind placebo-controlled study manner. They need to be replicated in a larger study group.